Following this logic, Lemdami et al had demonstrated an increase in specific T cell response, and significant tumor regression in CRC-LM patients receiving RFA in combination with in-situ immunotherapy or PD1/PDL1 blockade as adjuvant therapy.112 In addition, an increase in tumor antigen specific T cell infiltration and PDL1 expression in primary CRC tumors was observed in CRC-LM patients receiving RFA.113 Further explorations of the potential synergy of RFA and PD1/PDL1 blockade are required. The gene discussed is CD274; the disease is neoplasm.